🇺🇸 FDA
Patent

US 11439683

Anti-angiogenic therapy of metastatic colorectal cancer

granted A61KA61K38/179A61K45/06

Quick answer

US patent 11439683 (Anti-angiogenic therapy of metastatic colorectal cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/179, A61K45/06, A61P, A61P35/00